about
Chimeric antigen receptor T-cell therapies for lymphoma.Opportunities and challenges in the immunological therapy of pediatric malignancy: a concise snapshot.Syk inhibitors in clinical development for hematological malignancies.Multifaceted Role of Neuropilins in the Immune System: Potential Targets for ImmunotherapyAnti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients.Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy.Chimeric Antigen Receptor (CAR) T-Cell Therapy for Thoracic Malignancies.Building a Safer and Faster CAR: Seatbelts, Airbags, and CRISPR.Posttransplant chimeric antigen receptor therapy.Advances in immunotherapy for pediatric acute myeloid leukemia.Immunology: The patterns of T-cell target recognition.Rewiring T-cell responses to soluble factors with chimeric antigen receptors.Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia.Engineering therapeutic T cells to suppress alloimmune responses using TCRs, CARs, or BARs.Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer.Simian Immunodeficiency Virus (SIV)-Specific Chimeric Antigen Receptor-T Cells Engineered to Target B Cell Follicles and Suppress SIV Replication.A Jurkat 76 based triple parameter reporter system to evaluate TCR functions and adoptive T cell strategies.Versatile CAR T-cells for cancer immunotherapy.Cytokine release syndrome.High-throughput antibody engineering in mammalian cells by CRISPR/Cas9-mediated homology-directed mutagenesisCAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple MyelomaTreatment-naïve HPV+ head and neck cancers display a T-cell-inflamed phenotype distinct from their HPV- counterparts that has implications for immunotherapyImmunological-based approaches for cancer therapyCo-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumorsThe Potential of CAR T Cell Therapy in Pancreatic CancerCytokine release syndrome: grading, modeling, and new therapyVaccination With a FAT1-Derived B Cell Epitope Combined With Tumor-Specific B and T Cell Epitopes Elicits Additive Protection in Cancer Mouse Models
P2860
Q38600697-954A05C8-BE66-4A8F-8E5C-1A64CBC4B253Q38643300-457C0361-FD84-4DD6-BDDC-C5204116535BQ42011012-0449A2D3-17B7-4EDE-98EC-ECBA3FA3B10BQ42654195-04C1220A-98C7-4C02-96C9-4FC5D8B2EFF3Q47142244-0A7AB26F-356D-4225-8D4A-DEE3D47A9C1DQ47193084-41CB0F6E-418A-47B4-93DE-1F13493499FEQ47377609-9E97D2BA-7B69-4E9E-A11E-6ED4AAEACBE9Q47443955-FC46EA57-C87A-44AD-BFC7-C63FF3DD7262Q47550219-16A75652-D861-4309-BEEB-BCB7713A396AQ47930962-7FB3C254-3F81-4373-AA06-3B1A705B897CQ47998396-C42607EB-9155-424A-BB91-36FF15395DFDQ48152533-F8D10219-EE6D-4F0E-9714-1859D893DF99Q50531950-B1E5A1F6-FBF3-4F80-AF80-D17F58977F3EQ52336320-7A932B4F-DECF-43E3-86FF-D7943A4381F2Q52568663-428CF34C-9326-48F5-8A95-33512ABCAA78Q52608538-34034BC9-742F-4AC2-BB4F-533458009CD9Q55287219-88057A98-CAB4-48C0-9265-F23E2155F561Q55347731-6A41AC7D-ED59-4A3E-BA8A-38CDDAEDB281Q55438228-237B0856-25AD-4ADE-829D-709993CFB0E3Q56888745-E21FA563-EA22-4F26-829E-7E6E34FEBF6DQ56966447-20F21717-C332-48AC-9853-D6B711AF86C0Q57138281-AB7CCDF7-F0E9-4648-91B3-4BFC886F84F9Q57168423-9AA9350D-53F5-486E-BC7C-4299C9E34F93Q57176182-BBFDCE12-770E-4E02-9376-3FD0A80A90DAQ57492021-936E76E6-5918-4EC2-A1BB-F32DC97BF3CAQ58700983-781E74CD-AE48-49A1-904A-9BEB0E93F8B1Q58707546-9D71EC12-9261-491F-A396-355D60BD1B4F
P2860
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Therapeutic T cell engineering.
@en
type
label
Therapeutic T cell engineering.
@en
prefLabel
Therapeutic T cell engineering.
@en
P2093
P2860
P356
P1433
P1476
Therapeutic T cell engineering.
@en
P2093
Isabelle Rivière
Michel Sadelain
Stanley Riddell
P2860
P2888
P304
P356
10.1038/NATURE22395
P407
P577
2017-05-01T00:00:00Z